- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04110977
A Reminder App to Reduce Radiation Dermatitis Rates in Patients With Head-and-Neck Cancer (RAREST-02)
RAdiotherapy RElated Skin Toxicity: A Reminder App to Reduce Radiation Dermatitis Rates in Patients With Head-and-Neck Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
The goal of this trial is to investigate whether the addition of a reminder app to standard care leads to a reduction of dermatitis and oral mucositis during radio(chemo)therapy for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).
This is a randomized, active-controlled, parallel-group trial, which will compare the following treatments of radiation dermatitis (primary endpoint) and oral mucositis in patients with SCCHN: Standard care supported by a reminder app (Arm A) vs. standard care alone (Arm B). The primary endpoint is to investigate the rate of patients experiencing grade ≥2 radiation dermatitis at 60 Gy of radiotherapy, the minimum planned total dose for all patients receiving definitive or adjuvant radiotherapy for locally advanced SCCHN with curative intention. In addition, the following endpoints will be evaluated: Radiation dermatitis grade ≥2 at the end of radiation treatment (EOT), radiation dermatitis grade ≥3 at 60 Gy and EOT, quality of life, pain, and radiation-induced oral mucositis grade ≥2 and grade ≥3 at 60 Gy and at EOT. According to sample size calculations, 80 patients are required per arm within the full analysis set. Taking into account that 5% of patients will not qualify for full analysis set, 168 patients should be randomized. The impact of the reminder app will be considered clinically relevant, if the rate of grade ≥2 radiation dermatitis can be reduced from 85% to 65%.
If the addition of a reminder app to standard care will result in a significant reduction of radiation dermatitis and oral mucositis, it could become a helpful tool for patients during radiotherapy of for SCCHN.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dirk Rades, Professor
- Phone Number: 45400 +49 451 500
- Email: dirk.rades@uksh.de
Study Contact Backup
- Name: Carlos A Narvaez
- Phone Number: +49 451 500
- Email: carlos.narvaez@uksh.de
Study Locations
-
-
Niedersachsen
-
Hannover, Niedersachsen, Germany, 30449
- Recruiting
- Medical Practice for Radiotherapy and Radiation Oncology
-
Contact:
- Stefan Janssen, Priv.-Doz.
- Email: st-janssen@gmx.net
-
-
Schleswig-Holstein
-
Lübeck, Schleswig-Holstein, Germany, 23562
- Recruiting
- Dept. of Radiation Oncology, University of Lübeck
-
Contact:
- Dirk Rades, Professor
- Phone Number: 45400 +49 451 500
- Email: dirk.rades@uksh.de
-
Contact:
- Carlos A Narvaez
- Phone Number: 45401 +49 451 500
- Email: carlos.narvaez@uksh.de
-
-
-
-
-
Valencia, Spain
- Not yet recruiting
- Dept. of Radiation Oncology, Hospital Universitario y Politecnico La Fe,
-
Contact:
- Antonio J Conde, MD
- Email: antoniojconde@gmail.com
-
-
Vizcaya
-
Barakaldo, Vizcaya, Spain
- Not yet recruiting
- Department of Radiation Oncology, Cruces University Hospital/ Biocruces Health Research Institute
-
Contact:
- Jon Cacicedo, MC
- Email: JON.CACICEDOFERNANDEZBOBADILLA@osakidetza.eus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically proven squamous cell carcinoma of the head-and-neck (SCCHN)
- Indication for definitive or adjuvant radio(chemo)therapy
- Possession of and ability to use a smart phone
- Age ≥18 years
- Written informed consent
- Capacity of the patient to contract
Exclusion Criteria:
- Nasopharynx cancer
- Pregnancy, Lactation
- Treatment with epidermal growth factor receptor (EGFR)-antibodies (either given or planned)
- Expected non-compliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Standard Care supported by a Reminder App (Arm A)
Treatment with Standard Care supported by a Reminder App, starting at the beginning of radiotherapy.
|
This app will remind the patients four times a day to perform skin and mouth care.
Instructions are given how to properly perform skin and mouth care.
The patients may postpone each required care procedure for up to 2 hours.
Finally, the patients are asked to state for each procedure whether or not they performed it.
To increase the patients' motivation, they will earn points for each successfully performed care procedure.
|
Active Comparator: Standard Care alone (Arm B)
Treatment with Standard Care alone, starting at the beginning of radiotherapy.
|
This app will remind the patients four times a day to perform skin and mouth care.
Instructions are given how to properly perform skin and mouth care.
The patients may postpone each required care procedure for up to 2 hours.
Finally, the patients are asked to state for each procedure whether or not they performed it.
To increase the patients' motivation, they will earn points for each successfully performed care procedure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of radiation dermatitis grade ≥2
Time Frame: until 60 Gy of radiotherapy
|
at least moderate radiation-induced skin toxicity such as erythema and desquamation
|
until 60 Gy of radiotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of radiation dermatitis grade ≥2
Time Frame: at the end of radiotherapy
|
at least moderate radiation-induced skin toxicity such as erythema and desquamation
|
at the end of radiotherapy
|
Rate of radiation dermatitis grade ≥3
Time Frame: at 60 Gy of radiotherapy and at the end of radiotherapy
|
severe radiation-induced skin toxicity such as erythema and desquamation
|
at 60 Gy of radiotherapy and at the end of radiotherapy
|
Pain score
Time Frame: prior to radiotherapy, weekly during radiotherapy, at 60 Gy and at the end of radiotherapy
|
Pain within the radiation fields measured with a self-rating analogue scale ranging from 0 (no pain) to 10 (maximum pain) points; higher values represent worse outcomes.
|
prior to radiotherapy, weekly during radiotherapy, at 60 Gy and at the end of radiotherapy
|
Rate of radiation-induced oral mucositis grade ≥2
Time Frame: at 60 Gy of radiotherapy and at the end of radiotherapy
|
at least moderate radiation-induced inflammation of the oral mucosa
|
at 60 Gy of radiotherapy and at the end of radiotherapy
|
Rate of radiation-induced oral mucositis grade ≥3
Time Frame: at 60 Gy of radiotherapy and at the end of radiotherapy
|
severe radiation-induced inflammation of the oral mucosa
|
at 60 Gy of radiotherapy and at the end of radiotherapy
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dirk Rades, Professor, Dept. of Radiation Oncology, University of Lübeck, Germany
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RAREST-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiation Dermatitis
-
Chang Gung Memorial HospitalNot yet recruiting
-
German University in CairoAin Shams UniversityCompleted
-
China Medical University HospitalCompletedRadiation DermatitisTaiwan
-
Sheba Medical CenterFerring PharmaceuticalsCompleted
-
Apeiron BiologicsCompleted
-
Lutris Pharma Ltd.CompletedRadiation DermatitisUnited States
-
University of RochesterNational Cancer Institute (NCI)CompletedRadiation-induced Dermatitis
-
University of the PhilippinesRecruitingAcute Radiation DermatitisPhilippines
-
China Medical University HospitalNot yet recruitingBreast Cancer | Radiation Dermatitis
-
Pharm Olam Pharmaceuticals Ltd.UnknownPrevention of Radiation Induced Dermatitis.
Clinical Trials on mobile application (reminder app)
-
Cukurova UniversityNot yet recruitingPatient Acceptance of Health Care | Drug Compliance
-
University of British ColumbiaThe Craig H. Neilsen FoundationActive, not recruitingSpinal Cord Injuries | Self-Management | Mobile ApplicationCanada
-
Centro Cardiologico MonzinoFondazione Policlinico Universitario Agostino Gemelli IRCCS; IRCCS Policlinico... and other collaboratorsActive, not recruiting
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation in ChildrenCompletedPediatric Heart Transplantation | Pediatric Heart Transplant Recipients | Pediatric Cardiac TransplantationUnited States
-
Gillian GreshamRecruitingMelanoma | Sarcoma | Neoplasms | Lymphoma | Kidney Cancer | Leukemia | Cancer | Breast Cancer | Head and Neck Cancer | Gynecologic Cancer | Glioblastoma | Multiple Myeloma | Stress | Colorectal Cancer | Anxiety | Lung Cancer | Prostate Cancer | Bladder Cancer | Loneliness | Pancreas Cancer | Cancer Metastatic | Uterine Cancer | Social IsolationUnited States
-
University of California, San FranciscoSwim Across AmericaRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Childhood CancerUnited States
-
University of California, San FranciscoMount Zion Health FundNot yet recruitingHead and Neck Cancer | TrismusUnited States
-
Indiana UniversityNational Institute on Aging (NIA)TerminatedAlzheimer Disease | Mild Cognitive Impairment | Mild Memory DisturbanceUnited States
-
University of ValenciaCompletedObsessive-Compulsive DisorderSpain
-
Far Eastern Memorial HospitalCompleted